Prognose

Das durchschnittliche Kursziel der Analysten beträgt +45,71€(+15,72%). Der Median liegt bei +44,27€(+12,08%).

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

QGEN Stock Might Gain Following New Partnership With ID Solutions
QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership.» Mehr auf zacks.com
QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications. The combination of QIAGEN's global reach and automation expertise with the assay development and manu.» Mehr auf businesswire.com
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.» Mehr auf zacks.com

Im letzten Quartal hatte Qiagen NV einen Umsatz von 446,89 Mio€ und ein Nettoeinkommen von 83,89 Mio€